A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patients Who Express Both B7 and FasR
Phase of Trial: Phase I/II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs KAHR 102 (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors KAHR Medical
- 07 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2020.
- 07 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2020.
- 07 Mar 2017 Status changed from not yet recruiting to suspended.